ethylmethylhydroxypyridine-succinate and Angina--Unstable

The results of the study parameters lipid profile and C-reactive protein (C-RP) in patients with angina pectoris after applying meksykoru. Combined treatment with meksykoru to correct the atherogenic lipid profile and CRP helped reduce content CRP, total cholesterol, low-density lipoprotein cholesterol, triglycerides, factor aterohenosti and raise HDL cholesterol.

Topics: Angina, Stable; Angina, Unstable; Antioxidants; C-Reactive Protein; Cytoprotection; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Male; Middle Aged; Myocardial Ischemia; Pyridines; Treatment Outcome

The authors analyze their experience in the application of mexicor, a Russian cytoprotector, in 50patients with chronic coronary artery disease (CAD) and 51 patients with acute coronary syndrome. In additional to cytoprotective action, the use of mexidor in complex therapy of CAD lowers the functional activity of thrombocytes, eliminates high blood viscosity syndrome, and lowers low density lipoprotein cholesterol level. These favorable changes in hemorheological parameters improves myocardial perfusion, lowers the strength and frequency of coronary pain attacks, retards postinfarction left ventricular remodeling, and increases the quality of life of patients with various CAD forms.

Topics: Acute Disease; Adult; Angina, Unstable; Blood Platelets; Blood Viscosity; Chronic Disease; Coronary Artery Disease; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines